Abstract
We describe the successful management of Anncaliia algerae microsporidial myositis in a man with graft versus host disease after hemopoietic stem cell transplantation. We also summarize clinical presentation and management approaches and discuss the importance of research into the acquisition of this infection and strategies for prevention.
Keywords:
Anncaliia; Anncaliia algerae; Australia; New South Wales; fungi; graft versus host disease; immunosuppressed; infection; microsporidia; microsporidial myositis; myositis; parasites; stem cell transplant.
MeSH terms
-
Aged
-
Albendazole / therapeutic use*
-
Antiprotozoal Agents / therapeutic use*
-
Graft vs Host Disease / drug therapy
-
Graft vs Host Disease / etiology
-
Graft vs Host Disease / immunology
-
Graft vs Host Disease / pathology
-
Hematopoietic Stem Cell Transplantation / adverse effects*
-
Humans
-
Immunosuppressive Agents / therapeutic use
-
Male
-
Microsporidia / drug effects
-
Microsporidia / isolation & purification*
-
Microsporidia / pathogenicity
-
Myositis / diagnosis
-
Myositis / drug therapy*
-
Myositis / immunology
-
Myositis / microbiology
-
New South Wales
-
Spores, Fungal / drug effects
-
Spores, Fungal / isolation & purification*
-
Spores, Fungal / pathogenicity
-
Transplantation, Homologous
Substances
-
Antiprotozoal Agents
-
Immunosuppressive Agents
-
Albendazole